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Abstract 
Introduction 
Non-small cell lung cancer (NSCLC) arises when epithelial cells lining the bronchial 
tubes undergo aberrant cell growth due to up-regulation of programmed death (PD-1) 
ligands, thereby affording evasion of immune surveillance. Pembrolizumab, a mono-
clonal antibody, is an immune checkpoint inhibitor. By blocking PD-1 from binding 
its ligands, programmed death ligand (PD-L1) and programmed death 2 (PD-L2), 
pembrolizumab restores T-cell activation, enabling effective detection and destruction 
of tumour cells  
Methodology 
Published and grey literature were identified by searching the Cochrane Library, CRD 
Database, Embase, Ovid Medline, PubMed, Internet sites and contacting the manu-
facturer. Quality assessment was conducted to assess the risk of bias at the study level 
and the applicability of study results. Furthermore, the magnitude of clinically mean-
ingful benefit that can be expected from pembrolizumab was evaluated based on, both 
the original and adapted version of, the Magnitude of Clinical Benefit Scale developed 
by the European Society for Medical Oncology. 
Results of the KEYNOTE-189 trial 
In the phase III, KEYNOTE-189 study, 616 patients with untreated metastatic non-
squamous NSCLC without targetable epidermal growth factor receptor (EGFR) or an-
aplastic lymphoma kinase (ALK) aberrations, regardless of PD-L1 expression, were 
randomised 2:1 to pemetrexed and platinum-based chemotherapy plus either pem-
brolizumab or saline placebo every three weeks for four cycles, followed by pembroli-
zumab or placebo for 35 cycles plus pemetrexed maintenance therapy. Adding pem-
brolizumab to chemotherapy conferred longer overall survival (OS) than chemother-
apy alone (not reached versus 11.3 months). Compared with chemotherapy alone, pem-
brolizumab increased progression-free survival (PFS) by 3.9 months. Increased PFS 
was consistent across subgroups except for those with PD-L1 tumour proportion scores 
(TPS) <1% and those over 65 years of age. Pembrolizumab increased the overall re-
sponse rate (ORR) by 28.7% and the median duration of response (DOR) by 3.4 
months compared with chemotherapy alone. Anaemia and neutropenia were the most 
frequently reported adverse events (AEs) of grade ≥3 in severity. Common immune-
mediated AEs occurring in pembrolizumab combination patients included hypothy-
roidism (6.7%), hyperthyroidism (4.0%), colitis (2.2%), nephritis (1.7%), and hepatitis 
(1.2%).  
Conclusion 
Overall, adding pembrolizumab to platinum-based chemotherapy increases OS, PFS, 
and ORR, and reduces the risk of death and progression for patients with metastatic 
NSCLC. While the survival benefit of pembrolizumab combination over chemother-
apy alone was observed regardless of PD-L1 tumour expression, the greatest relative 
benefit was achieved in patients whose tumours exhibited higher PD-L1 levels. Due to 
cross-over, only relative 12 month OS data are available, absolute OS data are not and 
will not be available. Data regarding quality of life and central nervous system activity 
are needed to ensure patients derive a clinically relevant benefit over time despite man-
ageable toxicity. Without direct comparison trials, physicians may need to discuss 
whether adding pembrolizumab to platinum-based chemotherapy would provide 
greater individualised efficacy to a patient than pembrolizumab monotherapy.   
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1 Research questions 
The HTA Core Model
®
 for Rapid Relative Effectiveness Assessment of Phar-
maceuticals was used for structuring this report [1]. The Model organises 
HTA information according to pre-defined generic research questions. Based 
on these generic questions, the following research questions were answered in 
the assessment. 
 
Element ID Research question 
Description of the technology 
B0001 What is pembrolizumab? 
A0022 Who manufactures pembrolizumab? 
A0007 What is the target population in this assessment? 
A0020 For which indications has pembrolizumab received marketing authorisation? 
Health problem and current use 
A0002 What is the NSCLC? 
A0004 What is the natural course of NSCLC? 
A0006 What are the consequences of NSCLC for the society? 
A0023 How many people belong to the target population? 
A0005 What are the symptoms and the burden of NSCLC? 
A0003 What are the known risk factors for NSCLC? 
A0024 How is NSCLC currently diagnosed according to published guidelines and in practice? 
A0025 How is NSCLC currently managed according to published guidelines and in practice? 
Clinical effectiveness 
D0001 What is the expected beneficial effect of pembrolizumab on mortality? 
D0005 How does pembrolizumab affect symptoms and findings (severity, frequency) of NSCLC? 
D0006 How does pembrolizumab affect progression (or recurrence) of NSCLC? 
D0011 What is the effect of pembrolizumab on patients ̕ body functions? 
D0012 What is the effect of pembrolizumab on generic health-related quality of life? 
D0013 What is the effect of pembrolizumab on disease-specific quality of life? 
Safety 
C0008 How safe is pembrolizumab in relation to the comparator(s)? 
C0002 Are the harms related to dosage or frequency of applying pembrolizumab? 
C0005 
What are the susceptible patient groups that are more likely to be harmed through the 
use of pembrolizumab? 
A0021 What is the reimbursement status of pembrolizumab? 
 
 
 
 
EUnetHTA 
HTA Core Model® 
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2 Drug description 
Generic/Brand name/ATC code:  
Pembrolizumab/Keytruda
®
/MK-3475/L01XC18 
 
B0001: What is pembrolizumab? 
Up-regulation of programmed death 1 (PD-1) ligands in patients with tu-
mours increases the propensity for cancer cells to evade immune surveillance. 
Pembrolizumab, a monoclonal antibody, is an immune checkpoint inhibitor. 
By blocking PD-1 from binding its ligands, programmed death ligand 1 (PD-
L1) and programmed death ligand 2 (PD-L2), pembrolizumab restores T-cell 
activation, enabling effective detection and destruction of tumour cells [2]. 
Pembrolizumab is available as single-use vials of 50 mg powder for reconsti-
tution (25 mg/mL) or 100 mg/4 mL infusion solution. It is administered as an 
intravenous (IV) infusion over 30 minutes, at a dose of 200 mg every three 
weeks in combination with pemetrexed and platinum chemotherapy, for four 
cycles, followed by pembrolizumab (200 mg IV) plus pemetrexed every three 
weeks until progression or unacceptable toxicity [3, 4]. For melanoma and 
previously treated NSCLC, the dose depends on the patient’s weight and is 2 
mg/kg body weight [5]. 
Patients should be monitored for symptoms of immune-mediated pneumon-
itis, colitis, hepatitis, endocrinopathies, and nephritis. Dose interruption or 
discontinuation may be necessary in patients that develop pneumonitis, coli-
tis, hypophysitis, thyroid disorders, type 1 diabetes mellitus, nephritis, ele-
vated liver enzymes, inability to reduce corticosteroids to ≤10 mg/day within 
twelve weeks, infusion-related reactions, or intolerance due to adverse events 
(AEs) [3]. While systemic corticosteroids or immunosuppressants should be 
avoided prior to starting pembrolizumab, due to the potential for pharmaco-
dynamics interference, they may be used to treat immune-related AEs after 
starting pembrolizumab [6].  
 
A0022: Who manufactures pembrolizumab? 
Merck Sharp & Dohme Corporation, a subsidiary of Merck & Company In-
corporated 
 
 
 
3 Indication 
A0007: What is the target population in this assessment? 
Pembrolizumab (Keytruda
®
) is indicated, in combination with pemetrexed 
and platinum-based chemotherapy, for untreated patients with metastatic 
non-squamous non-small cell lung cancer (NSCLC) without epidermal 
PD-1 inhibitor, immune 
checkpoint inhibitor 
pembrolizumab (200 
mg IV) every 3 weeks + 
pemetrexed + 
chemotherapy for 4 
cycles, followed by 
maintenance therapy 
monitor for immune-
mediated AEs; withhold 
or discontinue for 
safety/tolerability  
previously untreated 
metastatic non-
squamous NSCLC  
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growth factor receptor (EGFR) mutations or anaplastic lymphoma kinase 
(ALK) rearrangements [4]. 
 
 
 
4 Current regulatory status 
A0020: For which indications has pembrolizumab received marketing author-
isation? 
Pembrolizumab was granted its first global approval by the US Food and 
Drug Administration (FDA) in September 2014 for the treatment of refrac-
tory unresectable or metastatic melanoma [7]. In October 2015, pembroli-
zumab was approved for the treatment of patients with metastatic NSCLC 
whose tumours express PD-L1 as determined by an FDA-approved test, with 
progression following platinum-based chemotherapy or targeted therapy for 
EGFR or ALK aberrations. The companion diagnostic, PD-L1 immunohisto-
chemistry (IHC) 22C3 pharmDx assay (Agilent Technologies, CA, USA), was 
approved concurrently and CE marked for European use. Approval was based 
on the overall response rate (ORR) in a subset of phase Ib KEYNOTE-001 
patients where at least 50% of tumour cells expressed PD-L1 (tumour propor-
tion score [TPS] ≥50%) and overall survival (OS) data from the phase III 
KEYNOTE-010 study [8-11].  
In October 2016, the FDA approved pembrolizumab as first-line therapy for 
metastatic NSCLC demonstrating high PD-L1 expression (TPS ≥50%) with-
out EGFR or ALK aberrations. Approval was based on progression-free sur-
vival (PFS) and OS data from the phase III KEYNOTE-024 study [12, 13]. 
The combination of pembrolizumab with pemetrexed and carboplatin had re-
ceived accelerated approval as first-line treatment for metastatic non-squa-
mous NSCLC irrespective of PD-L1 expression following results of the KEY-
NOTE-021 study in May 2017 [14]. Pembrolizumab is under priority review 
(expected September 2018) for use in combination with pemetrexed and plat-
inum chemotherapy as first-line treatment for metastatic non-squamous 
NSCLC based on results from the phase III KEYNOTE-189 study [15].  
Pembrolizumab received marketing authorisation by the European Medi-
cines Agency (EMA) in July 2015, and is approved for the treatment of meta-
static melanoma, advanced NSCLC, classical Hodgkin lymphoma, and 
urothelial cancer [5]. It is licensed as first-line monotherapy for metastatic 
NSCLC exhibiting high PD-L1 expression without EGFR or ALK aberra-
tions, and as second-line therapy following progression on platinum-based 
chemotherapy. A marketing authorisation application (MAA) to extend the 
use of pembrolizumab in combination with chemotherapy for NSCLC was 
withdrawn last October as further data were needed to derive conclusions re-
garding safety and efficacy [16]. However, pembrolizumab is currently under 
review in combination with pemetrexed and platinum-based chemotherapy 
as first-line treatment of patients with metastatic NSCLC based on OS data 
reported in the phase III KEYNOTE-189 trial [17].  
 
First global approval: 
FDA licensed for 
unresectable melanoma 
in September 2014 
FDA: licensed second-
line for metastatic 
NSCLC with PD-L1 
expression in October 
2015 
FDA: licensed first-line 
for metastatic NSCLC 
October 2016–May 2017 
FDA: priority review 
first-line in combination 
with chemotherapy for 
NSCLC in April 2018 
EMA approvals: first-
line for metastatic 
NSCLC with high PD-L1 
expression without 
EGFR/ALK aberrations, 
second-line following 
progression on 
platinum-based 
chemotherapy 
MAA: in combination 
with chemotherapy as 
first-line for NSCLC  
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5 Burden of disease 
A0002: What is NSCLC? 
NSCLC is the most common epithelial lung cancer and accounts for approxi-
mately 80–85% of all lung cancers. Adenocarcinoma, the most frequent histo-
logical type, has a survival rate of approximately 4–6% at five years [18, 19]. 
Approximately 7–35% of NSCLC patients have driver gene alterations in 
EGFR, ALK or ROS1, while 1–3% have BRAF mutations. The median survival 
for patients with metastatic disease without EGFR mutations or ALK rear-
rangements is approximately one year [20]. NSCLC tumours express the im-
mune checkpoint PD-L1 that negatively regulates T-cell proliferation and in-
duces cell death in tumour-specific T-cells. Among patients with treatment-na-
ïve, advanced NSCLC, 30% express PD-L1 in a high percentage of tumour cells 
(TPS ≥50%), while 30–50% of patients demonstrate a lower level of PD-L1 ex-
pression (TPS 1–49%) [9, 13, 14].  
 
A0004: What is the natural course of NSCLC? 
Lung cancer typically arises when epithelial cells lining the bronchial tubes 
undergo aberrant cell growth. To facilitate treatment, lung cancer is staged 
from I through IV based on tumour size, and presence or absence of lymph 
node involvement and metastases (TNM). Stage I lung cancer is <3 cm and 
localized to one lobe; stage II has spread to other parts of the lung or lymph 
nodes; stage III may be large or spread to lymph nodes between the lungs; and 
stage IV has metastasized to the adjacent bones, lung, brain, liver or any other 
organ [18, 21].  
 
A0006: What are the consequences of NSCLC for the society? 
Lung cancer is the second most commonly diagnosed cancer. While the im-
plementation of smoking cessation programs and multidisciplinary treat-
ments have reduced the incidence and mortality, 52–58% of lung cancer pa-
tients present with advanced-stage disease when curative treatment is no 
longer feasible. PD-L1 is a poor prognostic factor in NSCLC [22], leading to 
a high rate of relapse and early formation of micro-metastases [23].  
 
A0023: How many people belong to the target population? 
Lung cancer is the leading cause of cancer-related death in men and the sec-
ond in women worldwide. The age standardized incidence rate for the Euro-
pean Standard Population was 57.9 per 100,000 persons per year in 2015. In 
Austria, 2,956 men and 1,904 women were newly diagnosed with lung cancer 
in 2015; and 2,396 men and 1,493 women died due to lung cancer [24]. It was 
the second most common cancer in men and women (12% of all cancers). Ap-
proximately 6.2% of people will be diagnosed with lung cancer during their 
lifetime and approximately one-third of newly diagnosed patients have dis-
tant metastases. Assuming this, about 1,620 patients in Austria (2015) had 
metastatic NSCLC at the time of diagnosis. The average age at diagnosis is 
approximately 70 years [19].  
 
NSCLC accounts for 80–
85% of all lung cancers 
PD-L1 expression: 
TPS ≥50% in 30%;  
TPS 1–49% in 30–50% of 
patients 
staged I-IV by 
invasiveness 
metastasizes to bone, 
liver, brain, lymph nodes 
52–58% present with 
advanced cancer; 
relapse and metastasize 
early 
4,860 Austrians were 
diagnosed with NSCLC 
in 2015 
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A0005: What are the symptoms and the burden of disease or health condition? 
Many lung cancers are not symptomatic until they have spread. Symptoms of 
NSCLC include incessant cough, bloody sputum, chest pain, wheezing or 
hoarseness, weight loss or loss of appetite, shortness of breath, fatigue, and 
recurrent bronchitis or pneumonia. Lung cancer may metastasize to bone, 
brain, liver or lymph nodes causing pain, headaches, improper balance, sei-
zures, jaundice or lumps near the body’s surface [18]. 
 
A0003: What are the known risk factors for NSCLC? 
Overall, the risk of lung cancer increases with age, tobacco use, radiation ex-
posure, air pollution, and occupational exposure to asbestos, arsenic, chro-
mium beryllium, nickel, second-hand smoking and other agents. The risk of 
developing lung cancer is typically tenfold higher in smokers compared to 
lifetime non-smokers. Smoking cessation decreases precancerous lesions and 
reduces the risk of developing lung cancer [18, 25]. 
 
A0024: How is NSCLC currently diagnosed according to published guidelines 
and in practice? 
While some lung cancers may be found through screening, most are identified 
when they become symptomatic. Following a clinical history and physical 
exam, a chest x-ray may be done to identify any abnormal areas in the lungs. 
A computed tomography (CT) scan may show the size, shape and location of 
any lung tumours or enlarged lymph nodes, and guide a needle biopsy if a 
suspected area is identified. Lung cancer is diagnosed by examining cells de-
rived through biopsy, cytology or sputum sampling for the presence of cancer 
cells. IHC and molecular tests may be conducted to identify specific changes 
in the gene expression of cancer cells to target first-line treatment for NSCLC 
patients with genetic aberrations in EGFR or ALK genes. While a variety of 
assays are available to evaluate PD-L1 expression on tumour cells, PD-L1 
IHC 22C3 pharmDx is the only companion diagnostic that is approved by the 
FDA and CE marked for European use in guiding pembrolizumab therapy 
[9].  
 
 
 
6 Current treatment 
A0025: How is NSCLC currently managed according to published guidelines 
and in practice? 
Depending on the tumour stage, histology, and the patients’ overall health, 
surgery, radiation therapy and/or platinum-based chemotherapy may be used 
alone or in combination to treat NSCLC. Treatment per NSCLC stages in-
volves the following options [21]: 
 Stage I and II NSCLC patients typically undergo surgery to remove 
the cancer. Stage II patients and a subset of patients with stage Ib tu-
mours may benefit from postoperative adjuvant chemotherapy.  
NSCLC symptoms 
include: cough, chest 
pain, weight loss, 
shortness of breath 
main risk factor: 
smoking 
diagnosis: x-ray, CT and 
biopsy 
PD-L1 status: IHC assay 
treatment by NSCLC 
stage: surgery, radiation 
therapy, chemotherapy 
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 Patients with stage I or II cancers that are not surgical candidates, due 
to co-morbidities or limited lung function, may undergo local radia-
tion therapy.  
 Stage III NSCLC patients are highly heterogeneous and may undergo 
a combination of treatment modalities including chemotherapy and 
radiation and/or surgery depending on the extent and localization of 
disease.  
 Patients with stage IV disease are treated with systemic therapy or a 
symptom-based palliative approach.  
In appropriately selected patients, chemotherapy, molecularly targeted ther-
apy, and/or immunotherapy may be used to treat advanced or metastatic 
NSCLC [26, 27]: 
 While the optimal chemotherapy regimen for use with concurrent ra-
diotherapy is not known, cisplatin plus etoposide, carboplatin, or vi-
norelbine and paclitaxel are commonly used. Chemotherapy upregu-
lates PD-L1 expression on tumour cells, resulting in additive and syn-
ergistic antitumor activity. Combination pemetrexed and cisplatin is 
recommended for non-squamous NSCLC patients. 
 The standard dose fractionation regimen of radiotherapy with chemo-
therapy for stage III NSCLC is 60 Gy in 30 daily fractions. Intensity 
modulated radiation therapy is preferred over 3D radiotherapy due to 
the reduced risk for pneumonitis.  
 Patients with ALK translocations benefit from crizotinib, ceritinib, 
alectinib, lorlatinib or brigatinib therapy. First-line therapy for ROS1-
translocated NSCLC is crizotinib; cabozantinib, ceritinib or lorlatinib 
may be effective for crizotinib-resistant cancers. First-line therapy for 
stage IV patients with BRAF V600E is combination dabrafenib plus 
trametinib.  
 Patients with EGFR mutations may benefit from TKIs such as first 
generation erlotinib or gefitinib, or second-generation afatinib. Third 
generation TKI osimertinib also targets the EGFRT790M mutation as-
sociated with acquired resistance to EGFR-TKIs.  
 Pembrolizumab, nivolumab, atezolizumab, and durvalumab block 
PD-L1 on T-lymphocytes and are used as second-line therapies for ad-
vanced NSCLC. Pembrolizumab is recommended as first-line mono-
therapy for metastatic NSCLC exhibiting high PD-L1 expression 
without EGFR or ALK aberrations. Non-squamous NSCLC patients 
with low PD-L1 expression lacking driver mutations may benefit from 
pembrolizumab with pemetrexed and carboplatin or cisplatin. Pem-
brolizumab is currently under review in combination with pemetrexed 
and platinum-based chemotherapy as first-line treatment for meta-
static NSCLC. While combined nivolumab and ipilimumab afforded 
NSCLC patients with PD-L1 expression >1% in the CheckMate 227 
trial improved PFS compared with chemotherapy, further data is 
awaited to determine the role of nivolumab and ipilimumab in the 
first-line management of advanced NSCLC. 
 
advanced or metastatic 
NSCLC 
 
 
 
 
 
 
 
 
 
 
 
 
targeted therapies 
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7 Evidence 
A literature search was conducted on 18 June 2018 in five databases: the 
Cochrane Library, CRD Database, Embase, Ovid Medline and PubMed. 
Search terms were “pembrolizumab”, “keytruda”, “L01XC18”, “non small 
lung cancer”, “NSCLC”, “lung cancer” and “metastatic”. The manufacturer 
was also contacted and submitted no unpublished data, only information re-
garding ongoing trials found on clinicaltrials.gov. A manual search identified 
two statistical reports [19, 24], two FDA approval documents [3, 15], four 
EMA marketing authorization notifications [5, 6, 16, 17], eight clinical guid-
ance documents [18, 21-23, 25, 26, 28, 29], and six clinical trial articles [10, 
11, 14, 30-32] and a cost document [33]. Ongoing trials information was found 
on www.clinicaltrials.gov. 
Overall, 271 references were identified. Included in this reported are:  
 KEYNOTE-189, phase III [4, 31, 32] 
 KEYNOTE-024, phase III [13] 
 KEYNOTE-021, phase I/II [14]  
To assess the risk of bias at the study level, the assessment of the methodolog-
ical quality of the evidence was conducted based on the EUnetHTA internal 
validity for randomised controlled trials (RCTs) [34]. Evidence was assessed 
based on the adequate generation of the randomisation sequence, allocation 
concealment, blinding of patient and treating physician, selective outcome re-
porting and other aspects that may increase the risk of bias. Study quality 
details are reported in Table 5 of the Appendix. 
The external validity of the included trial was assessed using the EUnetHTA 
guideline on applicability of evidence in the context of a relative effectiveness 
assessment of pharmaceuticals, considering the following elements: popula-
tion, intervention, comparator, outcomes and setting [35]. 
To evaluate the magnitude of “meaningful clinical benefit” that can be ex-
pected from a new anti-cancer treatment, the Magnitude of Clinical Benefit 
Scale version 1.1 developed by the European Society for Medical Oncology 
(ESMO-MCBS v1.1) was used [36]. Additionally, an adapted version (due to 
perceived limitations) of the ESMO-MCBS was applied [37]. Details of the 
magnitude of the clinically meaningful benefit scale are reported in Table 3. 
 
systematic literature 
search in 5 databases:  
248 hits 
 
 
manual search: 23 
additional references 
overall: 271 references 
included: 3 studies 
study level risk of bias 
assessed based on 
EUnetHTA internal 
validity for RCTs 
assessment of the 
external validity based 
on the EUnetHTA 
guideline 
magnitude of clinically 
meaningful benefit 
assessed according to 
the ESMO-MCBS 
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7.1 Quality assurance  
This report has been reviewed by an internal reviewer and an external re-
viewer. The latter was asked for the assessment of the following quality crite-
ria: 
 How do you rate the overall quality of the report? 
 Are the therapy options in the current treatment section used in clin-
ical practice and are the presented standard therapies correct? 
 Is the data regarding prevalence, incidence, and amount of eligible 
patients correct? 
 Are the investigated studies correctly analysed and presented (data 
extraction was double-checked by a second scientist)? 
 Was the existing evidence from the present studies correctly inter-
preted? 
 Does the current evidence support the final conclusion? 
 Were all important points mentioned in the report? 
The LBI-HTA considers the external assessment by scientific experts from 
different disciplines a method of quality assurance of scientific work. The fi-
nal version and the policy recommendations are under full responsibility of 
the LBI-HTA. 
 
 
 
7.2 Clinical efficacy and safety –  
phase III studies 
KEYNOTE-189 (NCT02578680) is a multicentre, double-blind, randomised, 
interventional phase III study involving 616 patients with metastatic non-
squamous NSCLC without EGFR or ALK mutations and who have not been 
treated for metastatic disease [4]. The study was designed to evaluate whether 
adding pembrolizumab to pemetrexed and platinum-based chemotherapy 
prolongs PFS and OS compared to standard chemotherapy alone. Efficacy 
analyses were based on all randomly assigned patients comprising the intent-
to-treat (ITT) population. Safety analyses involved all patients who received 
at least one dose of the study drug; all randomly assigned patients received at 
least one dose of trial treatment.  
Eligible patients were 18 years or older, with untreated pathologically con-
firmed metastatic non-squamous NSCLC without EGFR or ALK mutations, 
and provided tumour samples for PD-L1 status determination. Patients were 
excluded if they had symptomatic central nervous system (CNS) metastases, 
a history of non-infectious pneumonitis requiring glucocorticoids, active au-
toimmune disease, were receiving systemic immunosuppressant therapy or 
had received more than 30 Gy of radiotherapy to the lung within the previous 
six months. Study participants were stratified by PD-L1 expression (TPS 
≥1% versus <1%), choice of platinum-based chemotherapy (cisplatin versus 
carboplatin), and smoking history (never versus former or current).  
internal and external 
review  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
quality assurance 
method 
 
KEYNOTE-189: 
pembrolizumab + 
chemotherapy versus 
chemotherapy alone as 
first-line treatment for 
metastatic NSCLC 
ITT (n = 616): stratified 
by PD-L1 expression, 
chemotherapy, and 
smoking history 
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Patients were randomised 2:1 to receive pemetrexed (500 mg/m
2
 IV) and plat-
inum-based chemotherapy physicians choice of cisplatin (75 mg/m
2
 IV) or 
carboplatin (area under the curve [AUC]) 5mg/mL/minute IV) plus either 
pembrolizumab (200 mg IV) or saline placebo every three weeks for four cy-
cles, followed by pembrolizumab or placebo for up to 35 cycles plus 
pemetrexed maintenance therapy. Cross-over to pembrolizumab monother-
apy was permitted for placebo combination patients with verified disease pro-
gression. Dose reductions or interruptions were allowed and one agent alone 
could be discontinued if it clearly caused toxicity. The mean (± standard de-
viation [SD]) duration of treatment (DOT) was 7.4 ± 4.7 months for patients 
receiving pembrolizumab combination and 5.4 ± 4.3 months for those receiv-
ing placebo combination.  
At data cut-off, 410 events of Response Evaluation Criteria in Solid Tumours 
(RECIST)-defined disease progression or death and 235 deaths had occurred. 
In the as-treated population, 33.8% (137/405) of pembrolizumab combination 
and 17.8% (36/202) placebo combination patients were still receiving as-
signed treatment. In the ITT population, 30.5% (125/410) of pembrolizumab 
combination and 46.6% (96/206) of placebo combination patients had re-
ceived subsequent therapy. In the placebo combination group, 32.5% (67/206) 
crossed over to pembrolizumab monotherapy following disease progression 
during the trial and 18 (8.7%) patients received immunotherapy outside of 
the trial. The cross-over rate was 41.3% in the ITT population and 50.0% in 
170 patients who discontinued all trial drugs. The median duration of follow-
up for OS was 10.5 months.  
The two primary endpoints were OS (time from randomisation to all-cause 
death) and PFS (time from randomisation to RECIST-defined disease pro-
gression or all cause death) as assessed by blinded independent central radio-
logic review (BICR). Secondary endpoints were overall response rate (ORR; 
percentage of patients with a confirmed complete [CR] or partial response 
[PR]), duration of response (DOR; time from first CR or PR to disease pro-
gression or death), and safety. Exploratory endpoints included the effect of 
PD-L1 expression on efficacy and patient-reported outcomes (PROs). Tu-
mours were assessed according to RECIST version 1.1 at weeks six and twelve, 
then every nine weeks through week 48 and every twelve weeks thereafter. 
Patients were contacted every twelve weeks to assess survival during follow-
up. AEs were graded for severity according to the National Cancer Institute 
Common Terminology Criteria (CTCAE) version 4.0.  
The ITT population (n = 616) had a median age of 64 years (range 34–84), 
60% were male, 61% were European, 88% were current or former smokers, 
18% had brain metastases, 30% had low PD-L1 expression (TPS 1–49%) and 
33% had high PD-L1 tumour expression (TPS ≥50%) at randomisation. De-
tailed patient characteristics including inclusion- and exclusion criteria can 
be found in Table 5 and study quality is described in Table 6 of the appendix, 
respectively. Clinical efficacy data are presented in Table 1 and AEs are listed 
in Table 2.  
 
 
 
 
200 mg pembrolizumab 
+ chemotherapy versus 
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mean DOT: 7.4  
months of 
pembrolizumab 
combination versus 5.4 
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secondary endpoints: 
ORR, DOR, and safety 
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7.2.1 Clinical efficacy 
 
D0001: What is the expected beneficial effect of pembrolizumab on mortality? 
The primary endpoint of BICR-assessed median OS was not reached in the 
pembrolizumab combination group and was 11.3 months (95% confidence in-
terval [CI] 8.7–15.1) in the placebo combination group (HR for death 0.49, 
95% CI 0.38–0.64; p < 0.001). Approximately 69.2% (95% CI 64.1–73.8) of 
the pembrolizumab combination group and 49.4% (95% CI 42.1–56.2) of the 
placebo combination group reached 12-month survival. The OS benefit of 
pembrolizumab combination over placebo combination was demonstrated 
across all subgroups, regardless of the level of PD-L1 tumour expression (n = 
190 TPS <1%, HR 0.59, 95% CI 0.38–0.92, p < 0.001; n = 186 TPS 1–49%, 
HR 0.55, 95% CI 0.34–0.90, p < 0.001; n = 202 TPS ≥50%, HR 0.42, 95% CI 
0.26–0.68, p < 0.001). The greatest relative benefit was observed in patients 
with a PD-L1 TPS ≥50%. While pembrolizumab improved OS for both sexes, 
women derived a slightly greater benefit than men (n = 253 women HR 0.29, 
95% CI 0.19–0.44, p < 0.001; n = 363 men, HR 0.70, 95% CI 0.50–0.99, p < 
0.001.) Due to cross-over, only relative 12 month OS data are available, abso-
lute OS data are not and will not be available. 
 
D0006: How does pembrolizumab affect progression (or recurrence) of 
NSCLC? 
The primary endpoint of BICR-assessed median PFS was 8.8 months (95% 
CI 7.6–9.2) in pembrolizumab combination patients versus 4.9 months (95% 
CI 4.7–5.5) in placebo combination patients (HR for progression or death 
0.52, 95% CI 0.43–0.64; p < 0.001). Approximately 34.1% (95% CI 28.8–39.5) 
of the pembrolizumab combination group and 17.3% (95% CI 12.0–23.5) of 
the placebo combination group reached 12-month PFS.  
The PFS benefit of pembrolizumab combination over placebo combination 
was demonstrated across predefined subgroups with the exceptions of those 
with a PD-L1 TPS <1% and those older than 65 years of age (n = 190 TPS 
<1%, HR for progression or death 0.75, 95% CI 0.53–1.05, p = no statistically 
significant difference between groups; n = 186 TPS 1–49%, HR 0.55, 95% CI 
0.37–0.81, p < 0.001; n = 202 TPS ≥50%, HR 0.36, 95% CI 0.25–0.52, p < 
0.001; n = 312 age <65 years, HR 0.43, 95% CI 0.32–0.56, p < 0.001; n = 304 
age ≥65 years, HR 0.75, 95% CI 0.55–1.02, p = no statistically significant 
difference between groups). 
 
D0005: How does pembrolizumab affect symptoms and findings (severity, fre-
quency) of NSCLC? 
The secondary endpoint of BICR-assessed ORR in the ITT population was 
47.6% (95% CI 42.6–52.5) in the pembrolizumab combination group and 
18.9% (95% CI 13.8–25.0) in the placebo combination group (estimated treat-
ment difference [ETD] 28.5, 95% CI 21.1–35.4; p < 0.0001; investigator-as-
sessed ORR ETD 23.2, 95% CI 15.8–30.1; p < 0.0001). The ORR benefit of 
pembrolizumab combination over placebo combination was consistent across 
all subgroups regardless of the level of PD-L1 tumour expression (n = 190 
TPS <1%, ETD 17.4, 95% CI 4.3–28.6, p < 0.0001; n = 186 TPS 1–49%, ETD 
28.5, 95% CI 13.9–41.4, p < 0.0001; n = 202 TPS ≥50%, ETD 38.5, 95% CI 
median OS: not reached 
for pembrolizumab 
combination vs. 
11.3 months for placebo 
combination 
 
consistent OS benefit 
regardless of level of 
PD-L1 expression 
median PFS: 8.8 months 
for pembrolizumab 
combination vs. 4.9 
months for placebo 
combination 
 
 
consistent PFS benefit 
across subgroups; 
except for TPS <1% and 
age >65 years 
ORR ITT: 
pembrolizumab 
combination: 47.6%  
placebo combination: 
18.9% 
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24.6–50.5, p < 0.0001). While the response rate was higher in the pembroli-
zumab combination group than in the placebo combination group across all 
categories of PD-L1 TPS, the greatest between-group difference was in pa-
tients with a TPS ≥50% (61.4% versus 22.9%). Investigator-assessed ORR was 
similar (estimated treatment difference [ETD] 28.5, 95% CI 21.1–35.4; p < 
0.0001). The disease control rate (DCR), proportion of patients with a con-
firmed complete or partial response, was 84.6% in the pembrolizumab com-
bination group and 70.4% in the placebo combination group. 
The BICR-assessed median time to response (TTR) was 2.2 months (95% CI 
1.1–11.1) in the pembrolizumab combination group and 1.4 weeks (95% CI 
1.2–11.1) the placebo combination group. The median DOR was 11.2 months 
(95% CI 1.1–18.0) in pembrolizumab combination patients and 7.8 months 
(95% CI 2.1–16.4) in placebo combination patients. Ongoing response was ob-
served in 112 (57.4%) of pembrolizumab combination patients versus 18 
(46.2%) of placebo combination patients. 
 
D0011: What is the effect of pembrolizumab on patients̕ body functions? 
Pembrolizumab may cause immune-mediated AEs including pneumonitis, 
colitis, hepatitis, endocrinopathies, and nephritis [3]. In the as-treated popu-
lation, pneumonitis was reported in 18 (4.4%) of pembrolizumab combination 
patients versus five (2.5%) of placebo combination patients. Immune-medi-
ated AEs occurring exclusively in the pembrolizumab combination group in-
clude colitis (2.2%), nephritis (1.7%), hepatitis (1.2%), hypophysitis (0.7%), 
pancreatitis (0.7%), myositis (0.2%), thyroiditis (0.2%), and type 1 diabetes 
mellitus (0.2%). Hypothyroidism, hyperthyroidism, and adrenal insufficiency 
were more commonly reported in the pembrolizumab combination group 
than the placebo combination group (27 [6.7%] versus 5 [2.5%], 16 [4.0%] 
versus 6 [3.0%], and 1 [0.2%] versus 1 [0.5%], respectively). Pembrolizumab 
may cause foetal harm based on its mechanism of action.  
 
D0012: What is the effect of pembrolizumab on generic health-related quality 
of life? 
No evidence was reported regarding the effect of pembrolizumab on generic 
health-related QoL.  
 
D0013: What is the effect of pembrolizumab on disease-specific quality of 
life? 
No evidence was reported regarding the effect of pembrolizumab on disease-
specific QoL.  
 
 
 
 
 
median DOR: 11.2 
months for 
pembrolizumab 
combination vs.  
7.8 months for placebo 
combination patients 
immune mediated AEs: 
pneumonitis, colitis, 
hepatitis, nephritis, 
pancreatitis, thyroid 
disorders, and 
endocrinopathies 
 
foetal toxicity 
generic health-related 
QoL: no evidence 
disease-specific QoL: no 
evidence 
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Table 1: Efficacy results KEYNOTE-189 [4, 31] 
Descriptive sta-
tistics and esti-
mate variabil-
ity 
Treatment group Pembrolizumab 
combination 
Placebo  
combination 
Number of subjects 410 206 
Progression or death at data cut-off, n  
Deaths at data cut-off, n  
410 
235 
BICR-assessed median OS, m (95% CI) 
  12 m OS %, (95% CI) 
  12 m OS, PD-L1 TPS <1%, %, (95% CI)  
  12 m OS, PD-L1 TPS 1–49%, %, (95% CI) 
  12 m OS, PD-L1 TPS ≥50%, %, (95% CI) 
NE (NE–NE) 
69.2 (64.1–73.8) 
61.7 (NR–NR) 
71.5 (NR–NR) 
73.0 (NR–NR) 
11.3 (8.7–15.1) 
49.4 (42.1–56.2) 
52.2 (NR–NR) 
50.9 (NR–NR) 
48.1 (NR–NR) 
BICR-assessed median PFS, m (95% CI) 
  12 m PFS, % (95% CI) 
8.8 (7.6–9.2) 
34.1 (28.8–39.5) 
4.9 (4.7–5.5) 
17.3 (12.0–23.5) 
BICR-assessed ORR, n, % (95% CI) 
  CR, n (%) 
  PR, n (%) 
  ORR, PD-L1 TPS <1%, %, (95% CI)  
  ORR, PD-L1 TPS 1–49%, %, (95% CI) 
  ORR, PD-L1 TPS ≥50%, %, (95% CI) 
Investigator-assessed ORR, n, % (95% CI) 
  CP, n (%) 
  PR, n (%) 
n = 195; 47.6 (42.6–52.5) 
2 (0.5) 
193 (47.1) 
32.3 (24.3–41.2) 
48.4 (39.5–57.4) 
61.4 (52.5–69.7) 
n = 175; 42.7 (37.8–47.6) 
2 (0.5) 
173 (42.2) 
n = 39; 18.9 (13.8–25.0) 
1 (0.5) 
38 (18.4) 
14.3 (6.7–25.4) 
20.7 (11.2–33.4) 
22.9 (13.7–34.4) 
n = 40; 19.4 (14.2–25.5) 
0 (0.0) 
40 (19.4) 
DCR (%) 84.6 70.4 
BICR-assessed median TTR, m, range 
Investigator-assessed median TTR, m, range 
2.2 (1.1–11.1) 
1.8 (1.1–11.3) 
1.4 (1.2-11.1) 
2.6 (1.2–9.0) 
BICR-assessed median DOR, m (range) 
Investigator-assessed median DOR, m (range) 
  BICR-assessed ongoing response, n (%) 
  Investigator-assessed ongoing response, n (%) 
11.2 (1.1–18.0) 
12.6 (1.1–18.1) 
112 (57.4) 
96 (54.9) 
7.8 (2.1–16.4) 
7.6 (1.6–15.5) 
18 (46.2) 
18 (45.0) 
Effect estimate 
per comparison 
 
Comparison groups 
Pembrolizumab combina-
tion versus Placebo combi-
nation 
OS 
(primary endpoint) 
HR for death 0.49 
95% CI 0.38–0.64 
Log-rank test p-value <0.001 
OS, PD-L1 TPS <1% 
(subgroup analysis, n = 190) 
HR  0.59 
95% CI 0.38–0.92 
Log-rank test p-value <0.001 
OS, PD-L1 TPS 1–49% 
(subgroup analysis, n = 186) 
HR  0.55 
95% CI 0.34–0.90 
Log-rank test p-value <0.001 
OS, PD-L1 TPS ≥50% 
(subgroup analysis, n = 202) 
HR  0.42 
95% CI 0.26–0.68 
Log-rank test p-value <0.001 
OS, male 
(subgroup analysis, n = 363) 
HR 0.70 
95% CI 0.50–0.99 
Log-rank test p-value <0.001 
OS, female 
(subgroup analysis, n = 253) 
HR 0.29 
95% CI 0.19–0.44 
Log-rank test p-value <0.001 
BICR-assessed PFS  
(primary endpoint) 
HR 0.52 
95% CI 0.43–0.64 
Log-rank test p-value <0.001 
PFS, PD-L1 TPS <1% 
(subgroup analysis, n = 190) 
HR 0.75 
95% CI 0.53–1.05 
Log-rank test p-value NS 
PFS, PD-L1 TPS 1–49% 
(subgroup analysis, n = 186) 
HR  0.55 
95% CI 0.37–0.81 
Log-rank test p-value <0.001 
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Effect estimate per 
comparison 
(continuation) 
PFS, PD-L1 TPS ≥50%  
(subgroup analysis, n = 202) 
HR  0.36 
95% CI 0.25–0.52 
Log-rank test p-value <0.001 
PFS, age <65 years 
(subgroup analysis, n = 312) 
HR 0.43 
95% CI 0.32-0.56 
Log-rank test p-value <0.001 
PFS, age ≥65 years 
(subgroup analysis, n = 304) 
HR 0.75 
95% CI 0.55-1.02 
Log-rank test p-value NS 
BICR-assessed ORR 
(secondary endpoint) 
ETD 28.5 
95% CI 21.1–35.4 
Log-rank test p-value <0.0001 
ORR, PD-L1 TPS <1% 
(subgroup analysis, n = 190) 
ETD 17.4 
95% CI 4.3–28.6 
Log-rank test p-value <0.0001 
ORR, PD-L1 TPS 1–49% 
(subgroup analysis, n = 186) 
ETD 28.5 
95% CI 13.9–41.1 
Log-rank test p-value <0.0001 
ORR, PD-L1 TPS ≥50% 
(subgroup analysis, n = 202) 
ETD 38.5 
95% CI 24.6–50.5 
Log-rank test p-value <0.0001 
Investigator-assessed ORR 
(secondary endpoint) 
ETD 23.2 
95% CI 15.8–30.1 
Log-rank test p-value <0.0001  
Abbreviations: BICR = blinded independent central review; CI = confidence interval; CR = complete response; DCR = disease control rate; DOR 
= duration of response; DOFU = duration of follow-up; ETD = estimated treatment difference; m = months; n = number; N = total number; NE 
= not evaluable; NR = not reported; NS = not significant; OR = odds ratio; ORR = objective response rate; OS = overall survival; PD-L1 = 
programmed death ligand 1; PFS = progression-free survival; PR = partial response; SD = stable disease; TPS = tumour proportion score 
 
 
7.2.2 Safety 
 
C0008: How safe is pembrolizumab in relation to the comparator(s)? 
In the safety population (n = 607), investigator-assessed AEs commonly re-
ported in the pembrolizumab- and placebo combination groups, respectively, 
included nausea (55.6% versus 52.0%), fatigue (40.7% versus 38.1%), consti-
pation (34.8% versus 31.7%), diarrhoea (30.9% versus 21.3%), decreased ap-
petite (28.1% versus 30.2%) and vomiting (24.2% versus 23.3%). AEs of grade 
≥3 severity observed in at least 10% of patients in the pembrolizumab com-
bination or the placebo combination group were anaemia (16.3% and 15.3%) 
and neutropenia (15.8% and 11.9%). The only AE of grade ≥3 reported more 
frequently in pembrolizumab combination patients was febrile neutropenia. 
Acute kidney injury was more common in the pembrolizumab combination 
group than in the placebo combination group (5.2% versus 0.5%). AEs that 
common AEs: nausea, 
fatigue, constipation, 
diarrhoea, decreased 
appetite and vomiting 
 
common grade ≥3 AEs: 
anaemia, neutropenia 
 
deaths due to AEs: 6.7% 
for pembrolizumab 
combination vs. 5.9% 
for placebo combination 
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resulted in death occurred in 27 of 405 (6.7%) pembrolizumab combination 
patients and in twelve of 202 (5.9%) placebo-combination patients.  
 
C0002: Are the harms related to dosage or frequency of applying 
pembrolizumab? 
AEs of grade ≥3 severity were observed in 67.2% and 65.8% of patients in the 
pembrolizumab- and placebo combination groups, respectively. Approxi-
mately 13.8% of pembrolizumab combination patients and 7.9% of placebo 
combination patients discontinued all trial drugs due to AEs, while 20.2% and 
10.4% discontinued pembrolizumab and placebo, respectively. In the pem-
brolizumab combination group, acute kidney injury of grade ≥3 severity, re-
ported in eight (2.0%) patients, led to the discontinuation of all trial thera-
pies.  
Pembrolizumab may cause severe or life-threatening infusion-related reac-
tions, including hypersensitivity and anaphylaxis [3]. Infusion-related reac-
tions were reported in 2.5% and 1.0% of patients in the pembrolizumab- and 
placebo combination groups, respectively.  
 
C0005: What are the susceptible patient groups that are more likely to be 
harmed through the use of pembrolizumab? 
Study participants had a median age of 64 years (range 34–84) with a good 
performance status (ECOG 0–1). Patients with a history of autoimmune dis-
ease, immunodeficiency, active infections or uncontrolled illnesses were ex-
cluded from study. Subgroup analysis by age demonstrated no statistically 
significant difference in PFS between study groups in patients older than 65 
years of age. The clinical specificity of elderly patients with comorbidities, co-
medication, reduced functional reserve and immunosenescence may affect 
the efficacy and or toxicity of immune-checkpoint inhibitors [38, 39]. 
Immune-mediated AEs occurred in 22.7% of pembrolizumab combination 
patients and 11.9% of placebo combination patients. Events of grade ≥3 se-
verity were reported in 8.9% and 4.5% of the pembrolizumab- and placebo 
combination groups, respectively. Three deaths incurred due to immune-me-
diated pneumonitis in the pembrolizumab combination group. While pa-
tients with compromised immune systems or autoimmune disease were ex-
cluded from the study population, side effects of greater severity may be ex-
pected in this population.  
Based on its mechanism of action, pembrolizumab may cause foetal harm and 
adverse reactions in breastfed infants. Females are advised to use effective 
contraception and not to breast feed for four months after taking their final 
dose [3].  
20% discontinued 
pembrolizumab due to 
AEs; 2.0% discontinued 
all drugs due to acute 
kidney injury  
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Table 2: Most frequent adverse events of KEYNOTE-189 [4] 
Adverse Event (according  
to CTCAE version 4.0) 
Pembrolizumab combination 
(n = 405) 
Placebo combination 
(n = 202) 
 Any Grade  
n (%) 
Grade 3, 4, or 5 
n (%) 
Any Grade  
n (%) 
Grade 3, 4, or 5 
n (%) 
Any event  404 (99.8) 272 (67.2) 200 (99.0) 133 (65.8) 
Discontinued all treatment due to AE 56 (13.8) 48 (11.9) 16 (7.9) 14 (6.9) 
Discontinued any treatment component due to AE 112 (27.7) 81 (20.0) 30 (14.9) 22 (10.9) 
Discontinued pembrolizumab or placebo 82 (20.2) 64 (15.8) 21 (10.4) 17 (8.4) 
Discontinued pemetrexed 93 (23.0) 69 (17.0) 23 (11.4) 17 (8.4) 
Discontinued platinum-based drug 31 (7.7) 27 (6.7) 12 (5.9) 10 (5.0) 
Event leading to death 27 (6.7) 27 (6.7) 12 (5.9) 12 (5.9) 
 AEs in ≥15% of patients in either group 
  Nausea 225 (55.6) 14 (3.5) 105 (52.0) 7 (3.5) 
  Anaemia 187 (46.2) 66 (16.3) 94 (46.5) 31 (15.3) 
  Fatigue 165 (40.7) 23 (5.7) 77 (38.1) 5 (2.5) 
     Constipation 141 (34.8) 4 (1.0) 64 (31.7) 1 (0.5) 
  Diarrhoea  125 (30.9) 21 (5.2) 43 (21.3) 6 (3.0) 
  Decreased appetite  114 (28.1) 6 (1.5) 61 (30.2) 1 (0.5) 
  Neutropenia  110 (27.2) 64 (15.8) 49 (24.3) 24 (11.9) 
  Vomiting  98 (24.2) 15 (3.7) 47 (23.3) 6 (3.0) 
  Cough 87 (21.5) 0 (0.0) 57 (28.2) 0 (0.0) 
  Dyspnoea 86 (21.2) 15 (3.7) 52 (25.7) 11 (5.4) 
  Asthenia 83 (20.5) 25 (6.2) 49 (24.3) 7 (3.5) 
  Rash 82 (20.2) 7 (1.7) 23 (11.4) 3 (1.5) 
  Pyrexia 79 (19.5) 1 (0.2) 30 (14.9) 0 (0.0) 
  Peripheral oedema 78 (19.3) 1 (0.2) 26 (12.9) 0 (0.0) 
  Thrombocytopenia 73 (18.0) 32 (7.9) 29 (14.4) 14 (6.9) 
  Increased lacrimation 69 (17.0) 0 (0.0) 22 (10.9) 0 (0.0) 
 AEs of interest in the as-treated population 
  Any event 92 (22.7) 36 (8.9) 24 (11.9) 9 (4.5) 
  Hypothyroidism 27 (6.7) 2 (0.5) 5 (2.5) 0 (0.0) 
  Pneumonitis 18 (4.4) 11 (2.7) 5 (2.5) 4 (2.0) 
  Hyperthyroidism 16 (4.0) 0 (0.0) 6 (3.0) 0 (0.0) 
  Infusion reaction 10 (2.5) 1 (0.2) 2 (1.0) 0 (0.0) 
  Colitis 9 (2.2) 3 (0.7) 0 (0.0) 0 (0.0) 
  Severe skin reaction 8 (2.0) 8 (2.0) 5 (2.5) 4 (2.0) 
  Nephritis 7 (1.7) 6 (1.5) 0 (0.0) 0 (0.0) 
  Hepatitis 5 (1.2) 4 (1.0) 0 (0.0) 0 (0.0) 
  Hypophysitis 3 (0.7) 0 (0.0) 0 (0.0) 0 (0.0) 
  Pancreatitis  3 (0.7) 2 (0.5) 0 (0.0) 0 (0.0) 
  Adrenal insufficiency 1 (0.2) 1 (0.2) 1 (0.5) 1 (0.5) 
  Myositis 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 
  Thyroiditis 1 (0.2) 0 (0.0) 0 (0.0) 0 (0.0) 
  Type 1 diabetes mellitus 1 (0.2) 1 (0.2) 0 (0.0) 0 (0.0) 
Abbreviations: AE = adverse event; CTCAE = common terminology for cancer adverse events 
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7.3 Clinical effectiveness and safety –  
further studies 
KEYNOTE-024 (NCT02142738) is an ongoing multicentre, randomised, 
open-label, phase III trial to evaluate the safety and efficacy of first-line pem-
brolizumab monotherapy versus platinum-based chemotherapy in 305 meta-
static NSCLC patients who were PD-L1-positive without targetable EGFR or 
ALK aberrations [13]. Patients were randomised 1:1 to pembrolizumab (200 
mg IV) every three weeks for 35 cycles or investigator’s choice of platinum-
based chemotherapy. Both cross-over to pembrolizumab following progres-
sion and treatment beyond RECIST-defined progression were allowed based 
on investigator-assessed continued clinical benefit. The primary endpoint was 
BICR-assessed PFS; secondary endpoints included OS, ORR and safety. Effi-
cacy was assessed in the ITT population while safety was assessed in the as-
treated population. Tumours were evaluated every nine weeks according to 
RECIST version 1.1. AEs were graded according to the CTCAE version 4.0.  
At a median follow-up of 11.2 months (range 6.3–19.7), median PFS was 10.3 
months (95% CI 6.7–not reached) for pembrolizumab versus 6.0 months (95% 
CI 4.2–6.2) for chemotherapy patients. The estimated OS rate at six months 
was 80.2% in the pembrolizumab group versus 72.4% in the chemotherapy 
group. Pembrolizumab statistically significantly improved PFS and OS com-
pared to platinum-based chemotherapy as first-line treatment for PD-L1-pos-
itive NSCLC (HR for progression or death, 0.50, 95% CI 0.37–0.68, p < 0.001; 
HR for death, 0.60, 95% CI 0.41–0.89, p = 0.005, respectively). Compared 
with chemotherapy, pembrolizumab increased the response rate (44.8% ver-
sus 27.8%, the median DOR (not reached [range 1.9+–14.5+] versus 6.3 
months (range 2.1+–12.6+] and reduced treatment-related AEs (73.4% ver-
sus 90.0%, respectively).  
KEYNOTE-021 (NCT02039674) is an ongoing multicentre, randomised, 
open-label, phase I/II multi-cohort study to assess the safety and efficacy of 
first-line pembrolizumab in combination with chemotherapy or immunother-
apy in patients with metastatic NSCLC. Cohort G, a randomised open-label, 
phase II study, was designed to evaluate pemetrexed and carboplatin, with or 
without pembrolizumab, in 123 patients with untreated non-squamous 
NSCLC without targetable EGFR or ALK aberrations [14]. Stratified by PD-
L1 expression (TPS <1% versus ≥1%), patients were randomised 1:1 to four 
cycles of pemetrexed (500 mg/m
2
 IV) and carboplatin (AUC 5 mg/mL/minute 
IV) with or without pembrolizumab (200 mg IV) every three weeks followed 
by pembrolizumab for 24 months with pemetrexed maintenance therapy 
while the chemotherapy arm received pemetrexed and carboplatin alone with 
pemetrexed maintenance therapy. Both cross-over to pembrolizumab follow-
ing progression and treatment beyond RECIST-defined progression were al-
lowed based on investigator-assessed continued clinical benefit. The primary 
endpoint was BICR-assessed ORR; secondary endpoints included PFS, DOR, 
OS, safety, and the correlation between PD-L1 expression and anti-tumour 
activity. Efficacy was assessed in the ITT population while safety was assessed 
in the as-treated population. Tumours were evaluated according to RECIST 
version 1.1 at baseline, every six weeks for 18 weeks, then every nine weeks 
through the first twelve months and every twelve weeks thereafter. AEs were 
graded according to the CTCAE version 4.0.  
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At a median follow-up of 10.6 months, pembrolizumab significantly improved 
the proportion of patients who achieved an objective response compared with 
chemotherapy alone (n = 33 [55%, 95% CI 42–68] versus n = 18 [29%, 95% 
CI 18–41]; ETD 26% [95% CI 9–42]; p = 0.0016). Median time to response 
was 1.5 months (IQR 1.4–2.8) for pembrolizumab plus chemotherapy versus 
2.7 months (IQR 1.4–2.8) for chemotherapy alone. Median DOR was not 
reached in either group; 29 (88%) of 33 responders in the pembrolizumab 
combination group and 14 (78%) of 18 responders in the chemotherapy alone 
group remained alive and progression-free at data cut-off. Analysis of ORR by 
PD-L1 expression showed consistent ORR benefit of pembrolizumab with 
chemotherapy over chemotherapy alone (TPS <1%, ETD 57%, 95% CI 34–
78 and TPS ≥1% ETD 54%, 95% CI 37–70). Pembrolizumab combination 
statistically significantly increased PFS compared to chemotherapy alone 
(HR 0.53, 95% CI 0.31–0.91; p = 0.010). Median PFS was 13.0 months (95% 
CI 8.3–not reached) for pembrolizumab combination and 8.9 months (95% CI 
4.4–10.3) for chemotherapy alone. At the time of data cut-off, 27 patients had 
died, 22% (13/60) of pembrolizumab plus chemotherapy patients and 22% 
(14/63) chemotherapy only patients. No difference in OS was noted between 
groups (HR 0.90, 95% CI 0.42–1.91; p = 0.39). 
The incidence of grade ≥3 treatment-related AEs was similar between groups 
(39% for pembrolizumab plus chemotherapy versus 25.8% for chemotherapy 
alone); the rate of discontinuation due to treatment-related AEs was also sim-
ilar (10.2% versus 12.9%, respectively). The most common grade ≥3 treat-
ment-related AEs in the pembrolizumab plus chemotherapy group were anae-
mia (12%), decreased neutrophil count (5%), acute kidney injury (3%), de-
creased lymphocyte count (3%), fatigue (3%), neutropenia (3%), sepsis (3%), 
and thrombocytopenia (3%). Grade ≥3 immune-mediated AEs were reported 
in 3.4% and 1.6% of pembrolizumab combination and chemotherapy alone 
patients, respectively. The most common immune-mediated AEs of any grade 
in the pembrolizumab combination group were hypothyroidism (15%), hy-
perthyroidism (15%), and pneumonitis (5%). One treatment-related death oc-
curred in the pembrolizumab plus chemotherapy group due to sepsis.  
 
 
 
8 Estimated costs 
A0021: What is the reimbursement status of pembrolizumab? 
In Austria, single-use vials of 50 mg pembrolizumab powder for reconstitu-
tion (25 mg/mL) are available at a cost of € 1,714.00 (ex-factory price) [33]. 
Administered as an intravenous infusion, a 200 mg dose of pembrolizumab 
would cost € 6,856.00, every three weeks when used in combination with 
pemetrexed and platinum therapy, for four cycles, followed by pembroli-
zumab plus pemetrexed every three weeks for up to 35 cycles. A mean dura-
tion of pembrolizumab treatment of 7.4 months would cost approximately € 
50,734.40. Pembrolizumab is indicated for metastatic NSCLC exhibiting PD-
L1 expression without EGFR or ALK aberrations. Since up to 50% of treat-
ment-naïve, advanced NSCLC express PD-L1 [9, 13, 14] and approximately 
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1,620 patients in Austria (2015) had metastatic NSCLC at diagnosis, pembroli-
zumab would cost approximately € 41,094,864.40 (7.4 month treatment period) 
annually with additional costs for chemotherapy and molecular testing. 
 
 
 
9 Ongoing research 
Several studies are ongoing to investigate pembrolizumab as monotherapy or 
in combination with other targeted therapies or immunotherapies to treat var-
ious stages of NSCLC. In July 2018, searches of www.clinicaltrials.gov and 
www.clinicaltrialsregister.eu using the search terms “pembrolizumab” and 
“non-small cell lung cancer” yielded 113 other registered studies (one phase 
IV, eleven phase III, 100 phase I/II, and one pembrolizumab PET-imaging 
study). Most studies were industry-sponsored or conducted in collaboration 
with industry. 
Selected recently completed and ongoing phase III or II studies evaluating 
pembrolizumab in patients with PD-L1-positive advanced NSCLC as first-
line monotherapy (KEYNOTE-042), in combination with carboplatin and 
paclitaxel or nab-paclitaxel (KEYNOTE-407), epacadostat with platinum-
based chemotherapy (KEYNOTE-715-05) and ipilimumab (KEYNOTE-598), 
in combination with platinum-based therapy for resectable NSCLC (KEY-
NOTE-671), and after resection with or without standard adjuvant therapy 
(KEYNOTE-091): 
 NCT02220894: KEYNOTE-042 is a phase III, randomised, open-la-
bel, parallel-group study of OS comparing pembrolizumab versus 
platinum-based chemotherapy as first-line treatment for PD-L1-pos-
itive advanced or metastatic NSCLC. Estimated study completion 
date is January 2020.  
 NCT02775435: KEYNOTE-407 is a phase III, randomised, double-
blind, parallel-group study to evaluate the safety and efficacy of car-
boplatin and paclitaxel or nano particle albumin-bound paclitaxel 
(nab-paclitaxel) with or without pembrolizumab as first-line treat-
ment for metastatic squamous NSCLC. Estimated study completion 
date is February 2021. 
 NCT03322566: KEYNOTE-715-05 is a phase II, randomised, double-
blind study to assess the efficacy and safety of pembrolizumab plus 
epacadostat with platinum-based chemotherapy versus pembroli-
zumab plus platinum-based chemotherapy plus placebo as first-line 
therapy in patients with metastatic NSCLC. Estimated study com-
pletion date is October 2021. 
 NCT03302234: KEYNOTE-598 is a phase III, randomised, double-
blind trial to determine the efficacy of pembrolizumab in combina-
tion with either ipilimumab or placebo as first-line treatment in pa-
tients with metastatic NSCLC. Estimated study completion date is 
February 2024.  
 NCT03425643: KEYNOTE-671 is a phase III, randomised, double-
blind trial to evaluate the safety and efficacy of pembrolizumab in 
113 registered studies 
6 phase II/III studies 
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combination with platinum-based chemotherapy before surgery fol-
lowed by pembrolizumab alone after surgery in patients with resec-
table NSCLC. Estimated study completion date is June 2026. 
 NCT02504372: KEYNOTE-091 (PEARLS) is a phase III, random-
ised, double-blind study to assess the safety and efficacy of pembroli-
zumab versus placebo in early stage NSCLC after resection and com-
pletion of standard adjuvant therapy. Estimated study completion 
date is August 2021.  
 
 
 
10 Discussion 
Between 2014 and 2015, pembrolizumab was licensed, by the FDA and the 
EMA, as first-line monotherapy for PD-L1-positive metastatic NSCLC with-
out EGFR or ALK aberrations (TPS ≥50%), and as second-line therapy for 
PD-L1-positive NSCLC with progression following platinum-based chemo-
therapy (TPS >1%). Approved concurrently, PD-L1 ICH 22C3 pharmDx is 
the only FDA and CE marked companion diagnostic assay for guiding pem-
brolizumab therapy [9]. First-line monotherapy approval was based on PFS 
and OS data from KEYNOTE-024 [12, 13]. While accelerated approval of 
pembrolizumab in previously treated patients was based on ORR correlated 
with PD-L1 expression in a subset of KEYNOTE-001 patients, full approval 
was granted based on OS data from KEYNOTE-010 [8-11]. The combination 
of pembrolizumab with pemetrexed and carboplatin received accelerated ap-
proval as first-line treatment for metastatic non-squamous NSCLC irrespec-
tive of PD-L1 expression following results of the KEYNOTE-021 study [14]. 
Pembrolizumab is under review, by the FDA and EMA, for use in combina-
tion with pemetrexed and platinum chemotherapy as first-line treatment for 
metastatic non-squamous NSCLC based on results from the phase III KEY-
NOTE-189 study [15].  
KEYNOTE-189, a randomised, double-blind, phase III study compared the 
efficacy and safety of pembrolizumab (500 mg/m
2
 IV) with platinum-based 
chemotherapy (cisplatin or carboplatin + pemetrexed) versus saline placebo 
with platinum-based chemotherapy as treatment for 616 patients with meta-
static non-squamous NSCLC regardless of PD-L1 expression who have not 
received any therapy for metastatic disease [4]. Adding pembrolizumab to 
chemotherapy conferred to a longer OS than chemotherapy alone (not 
reached versus 11.3 months, respectively), with a HR for death of 0.49. While 
the survival benefit of pembrolizumab combination over chemotherapy alone 
was demonstrated across all subgroups, regardless of PD-L1 tumour expres-
sion, patients with a PD-L1 TPS ≥50% derived the greatest relative benefit. 
While cancer immunotherapy generally affords a slightly better OS for males 
than females based on sex-related dimorphism in immune system response 
[40], pembrolizumab combination offered a slightly greater survival benefit 
for women than for men [4]. Due to cross-over, only relative 12 month OS data 
are available, absolute OS data are not and will not be available. 
FDA and EMA:  
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under review: first-line 
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Horizon Scanning in Oncology 
26 LBI-HTA | 2018 
Compared with chemotherapy alone, pembrolizumab increased PFS by 3.9 
months and lowered the risk of disease progression or death by 48%. The in-
crease in PFS was consistent across subgroups except for those with PD-L1 
expression on less than 1% of tumour cells (TPS <1%) and those older than 
65 years of age. Pembrolizumab improved the BICR-assessed response rate 
(RR) by 28.7% compared with chemotherapy alone, and increased the median 
DOR by 3.4 months. While the response rate was higher in the pembroli-
zumab combination group than the placebo combination group across all cat-
egories of PD-L1 TPS, patients with TPS ≥50% derived the greatest benefit 
(61.4% versus 22.9%, respectively). Adding pembrolizumab increased the 
DCR by 14.2% compared with chemotherapy alone. 
Commonly reported AEs in pembrolizumab combination patients included 
nausea, fatigue, constipation, diarrhoea, decreased appetite, and vomiting. 
Anaemia and neutropenia were the most frequently reported AEs of grade ≥3 
in severity. Immune-mediated AEs occurring exclusively in pembrolizumab 
combination patients included colitis (2.2%), nephritis (1.7%), hepatitis 
(1.2%), hypophysitis (0.7%), pancreatitis (0.7%), myositis (0.2%), thyroiditis 
(0.2%), and type 1 diabetes mellitus (0.2%). Hypothyroidism (6.7%), hyper-
thyroidism (4.0%) and adrenal insufficiency (0.2%) were also more commonly 
reported in pembrolizumab combination patients. Compared with placebo 
combination, more pembrolizumab combination patients discontinued all 
trial drugs (13.8% versus 7.9%) or solely the study drug (20.2% versus 10.4%, 
respectively) due to AEs. Acute kidney injury of grade ≥3 in severity caused 
2.0% of patients to discontinue therapy. AEs resulted in death in 6.7% of pem-
brolizumab combination patients, including three deaths due to immune-me-
diated pneumonitis.  
The results of KEYNOTE-189 hold some limitations. No evidence was re-
ported regarding the effect of pembrolizumab on generic or disease-specific 
QoL. However, QoL measures are needed to ensure patients achieve a clini-
cally relevant benefit over time despite manageable toxicity. While approxi-
mately 18% of patients were presented with brain metastases at baseline, no 
results were reported regarding the CNS activity of pembrolizumab. This is 
of substantial importance as NCLC patients frequently present with brain 
metastases and there is concern regarding the ability of pembrolizumab to 
penetrate the blood brain barrier [41]. Generalizability of the results may be 
limited in that while study participants had a median age of 64 years with a 
good performance status, the average age at diagnosis is 70 years in clinical 
practice. The clinical activity in elderly patients with comorbidities, autoim-
mune disease, reduced functional reserve, and immunosenescence may affect 
the efficacy and/or toxicity of pembrolizumab. Based on results of the KEY-
NOTE-024 study in October 2016, pembrolizumab became a first-line mono-
therapy option for patients with metastatic NSCLC whose tumours express 
high levels of PD-L1 [12, 13]. Without direct comparison trials, physicians 
and patients may need to discuss whether adding pembrolizumab to 
pemetrexed and platinum-based therapy would provide greater individual-
ised efficacy than pembrolizumab monotherapy. 
KEYNOTE-189 is a phase III trial with few methodological limitations. There 
was no risk of bias in the generation of randomisation sequence or allocation 
concealment. Patients were randomly assigned 2:1 to pembrolizumab combi-
nation or placebo combination using an interactive voice/web-based response 
system [32]. Patients, physicians and outcome assessors were blinded as they 
received ready-to-use blinded pembrolizumab or saline infusion solutions 
packed identically by an un-blinded pharmacist. The central imaging vendor 
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was blinded to treatment assignment to minimize bias in response assess-
ments. Selective outcome reporting is unlikely as the primary endpoints of 
OS and PFS, and secondary endpoints of ORR, DOR, investigator-assessed 
PFS and safety were reported as specified in the protocol. The risk of bias may 
be increased by industry involvement in funding the study, assisting with 
study design, defining immune-mediated AEs, data collection, analysis and 
interpretation, investigator-assessed safety analysis, as well as due to cross-
over (67 patients switched to pembrolizumab combination).  
Given the non-curative treatment setting of pembrolizumab and the statisti-
cally significant co-primary endpoint PFS, we applied Form 2b of the ESMO-
MCBS, since median OS was not reached at the time of analysis. We applied 
the ESMO-MCBS in order to assess whether pembrolizumab satisfies the cri-
teria for a “meaningful clinical benefit” (score 4 or 5). Both the original v1.1 
as well as the adapted version of the MCBS were applied. The application of 
the scale to the KEYNOTE-189 study resulted in a grade 3 in both the original 
and the adapted version of the ESMO-MCBS, respectively. Therefore, pem-
brolizumab leads to no “meaningful clinical benefit” according to the original 
scale or the adapted framework. 
The clinical efficacy and safety data from KEYNOTE-189 are consistent with 
previous studies that suggest pembrolizumab improves OS, PFS, and ORR 
with manageable toxicity in untreated PD-L1-positive metastatic NSCLC pa-
tients lacking EGFR or ALK aberrations. In the phase III KEYNOTE-024 
study, pembrolizumab monotherapy improved PFS and OS, and was associ-
ated with fewer AEs compared with platinum-based chemotherapy in NSCLC 
patients with high PD-L1 expressing tumours [13]. In cohort G of the phase 
I/II KEYNOTE-021 study, pembrolizumab plus pemetrexed and carboplatin 
statistically significantly improved the ORR and PFS compared to chemo-
therapy alone in non-squamous NSCLC patients [14]. Consistent with exist-
ing studies of PD-L1 inhibition, KEYNOTE-001 [10] and KEYNOTE-010 
[11], survival benefit was observed across all PD-L1 subgroups; however, the 
greatest relative benefit was achieved in patients with TPS ≥50%. While out-
comes in the placebo-combination group appeared poorer than those reported 
in patients who had received platinum-based chemotherapy in previous stud-
ies, the DCR and PFS were consistent with other studies [13]. Excluding ne-
phritis and acute kidney injury common with platinum-based chemotherapy, 
the incidence of most immune-mediated AEs was in keeping with those pre-
viously observed with pembrolizumab monotherapy [10, 11, 13]. 
Several studies are underway to investigate pembrolizumab as monotherapy 
or in combination with other targeted therapies or immunotherapies to treat 
various stages of NSCLC. Ongoing phase III trials, KEYNOTE-042 and KEY-
NOTE-407 are comparing pembrolizumab versus platinum-based chemother-
apy, and carboplatin and paclitaxel or nab-paclitaxel with or without pem-
brolizumab as first-line therapy for metastatic NSCLC, respectively. The ef-
ficacy and safety of pembrolizumab in combination with epacadostat and 
chemotherapy versus pembrolizumab and chemotherapy is under investiga-
tion in the phase II KEYNOTE-715-05 study. KEYNOTE-598 is evaluating 
the efficacy of pembrolizumab in combination with ipilimumab or placebo as 
first-line treatment for metastatic NSCLC. Phase III trials KEYNOTE-671 
and KEYNOTE-091 are investigating pembrolizumab and chemotherapy be-
fore surgery followed by pembrolizumab alone after surgery in patients with 
resectable NSCLC and pembrolizumab versus placebo in early stage NSCLC 
after resection. 
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Administered as an intravenous infusion, the recommended dose of 200 mg 
of pembrolizumab costs € 6,856.00 every three weeks when used in combina-
tion with pemetrexed and platinum therapy, for four cycles, followed by pem-
brolizumab plus pemetrexed every three weeks for up to 35 cycles. A mean 
duration of treatment of 7.4 months would cost approximately € 50,734.40. 
Since up to 50% of untreated, advanced NSCLC express PD-L1 and approx-
imately 1,620 patients in Austria (2015) had metastatic NSCLC at diagnosis, 
pembrolizumab would cost approximately € 41,094,864.40 (7.4 month treat-
ment period) annually with additional costs for chemotherapy and molecular 
testing.  
Elevated PD-L1 expression is commonly used as a biomarker of therapeutic 
efficacy for pembrolizumab, nivolumab and atezolizumab. At least four mon-
oclonal antibodies (clones 22-C3, 28-8, SP142, and SP263) have been devel-
oped as companion diagnostics of different PD-1 or PD-L1 inhibitors. Re-
search comparing these four antibodies on different staining platforms 
demonstrates that three of four reagents are comparable in terms of sensitiv-
ity, specificity and reproducibility [42]. Standardization of PD-L1 testing is 
warranted due to the availability of various staining techniques, antibodies, 
and differing levels of positivity. There is currently no consensus on a thresh-
old defining PD-L1 positivity, multiple definitions that are used hamper com-
parison across studies. PD-L1 is not an ideal biomarker because of its dy-
namic status, it is inducible by interferon exposure, therefore tumours that do 
not express PD-L1 at baseline may become PD-L1-positive as a result of an 
inflammatory background [43]. In addition to PD-L1 expression, novel bi-
omarkers are needed to identify patients most likely to benefit from pembroli-
zumab therapy. Total mutation burden [44], T-cell inflamed gene expression 
profile, PD-L2 expression, history of smoking and presence of specific tumour 
neoantigens may be useful in predicting response to therapy [41]. Further re-
search is needed regarding the mechanisms of primary and secondary re-
sistance to identify the optimal treatment approach after first-line pembroli-
zumab and to evaluate the efficacy and safety of pembrolizumab in the real-
world setting. 
Overall, KEYNOTE-189 is the first phase III, randomized, double-blind study 
to demonstrate that adding pembrolizumab to platinum-based chemotherapy 
increases OS, PFS, and ORR, and reduces the risk of death and progression 
for patients with metastatic NSCLC. While the survival benefit of pembroli-
zumab combination over chemotherapy alone was observed regardless of PD-
L1 tumour expression, the greatest relative benefit was achieved in patients 
whose tumours exhibited higher PD-L1 levels. Due to cross-over, only relative 
12 month OS data are available, absolute OS data are not and will not be avail-
able. Data regarding QoL and CNS activity are needed to ensure patients de-
rive a clinically relevant benefit over time despite manageable toxicity. Fur-
ther biomarkers are needed to ensure the appropriate selection of patients 
most likely to benefit from treatment and facilitate comparison with other 
immune checkpoint inhibitors. Without direct comparison trials, physicians 
may need to discuss whether adding pembrolizumab to platinum-based 
chemotherapy would provide greater individualised efficacy to a patient than 
pembrolizumab monotherapy.  
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Table 3: Benefit assessment based on original ESMO-MCBS v1.1 and adapted benefit assessment based on adapted ESMO-MCBS [36, 37] 
ESMO-
MCBS 
Active  
substance Indication Intention PE Form 
MG standard 
treatment 
Efficacy Safety 
AJ FM 
MG months 
HR 
(95% CI) Score calculation PM Toxicity QoL 
Adapted 
ESMO-
MCBS 
Pembrolizumab NSCLC NC 
OS 
& 
PFS1 
2b ≤6 months +3.9 months 0.52 0.43–0.64 
HR ≤0.65 AND 
Gain ≥1.5 months 
3 +1.4% grade 3–4 AEs, +5.9% discontinuation - - 3 
Original 
ESMO-
MCBS 
Pembrolizumab NSCLC NC 
OS 
& 
PFS1 
2b ≤6 months +3.9 months 
0.52 
0.43–0.64 
HR ≤0.65 AND 
Gain ≥1.5 months 
3 - - - 3 
Abbreviations: AJ = Adjustments, CI = confidence interval, FM = final adjusted magnitude of clinical benefit grade, HR = hazard ratio, m = months, MG = median gain, NSCLC = non-small-cell lung cancer, PE = primary 
endpoint, PM = preliminary magnitude of clinical benefit grade, QoL = quality of life 
 
DISCLAIMER 
The scores achieved with the ESMO Magnitude of Clinical Benefit Scale are influenced by several factors: by the specific evaluation form used, by the confidence interval (CI) of the endpoint of 
interest, and by score adjustments due to safety issues. Ad form: Every individual form measures a different outcome. The meaning of a score generated by form 2a is not comparable to the exact 
same score resulting from the use of form 2c. To ensure comparability, we report the form that was used for the assessment. Ad CI: The use of the lower limit of the CI systematically favours 
drugs with a higher degree of uncertainty (broad CI). Hence, we decided to avoid this systematic bias and use the mean estimate of effect. Ad score adjustments: Cut-off values and outcomes that 
lead to an up- or downgrading seem to be arbitrary. In addition, they are independent of the primary outcome and, therefore, a reason for confounding. Hence, we report the adjustments 
separately. 
 
                                                             
1
 Progression-free survival was used to evaluate the clinical benefit of pembrolizumab, since median overall survival was not reached at the time of scoring. 
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Table 4: Administration and dosing of pembrolizumab combination or placebo combination [3, 4, 6, 32] 
 Pembrolizumab combination Placebo combination 
Admin-
istration 
mode 
Pembrolizumab IV over 30 minutes, prior to same day 
chemotherapy [3] Matching saline placebo [4] 
Descrip-
tion of 
packaging 
50 mg white lyophilized powder in a single-dose vial for re-
constitution using 2.3 mL of sterile water (resulting con-
centration 25 mg/mL); 100 mg/4mL (25 mg/mL) colourless 
solution in a single-dose vial; withdraw required volume 
from vial and transfer into IV bag containing 0.9% sodium 
chloride injection, USP or 5% dextrose injection, USP, (fi-
nal concentration 1mg/mL-10 mg/mL) [3] 
Ready-to-use blinded matching saline placebo infu-
sion solution packaged identically to maintain blind-
ing [32] 
Total vol-
ume con-
tained in 
packaging 
for sale 
50 mg pembrolizumab powder formulated in 3.1 mg L-his-
tidine, 0.4 mg polysorbate 80 and 140 mg sucrose in a sin-
gle-dose vial; 100 mg pembrolizumab in 4 mL of solution 
in a single dose vial [3] 
Matching saline placebo [4] 
Dosing 
Pemetrexed + PC platinum-based chemotherapy + pem-
brolizumab (200 mg IV) every 3 weeks for 4 cycles, fol-
lowed by pembrolizumab for up to 35 cycles + pemetrexed 
maintenance therapy [4]. Discontinue pembrolizumab in 
patients with life-threatening AEs, grade 3/4 or recurrent 
pneumonitis, grade 3/4 nephritis, AST or ALT >5xULN or 
bilirubin >3xULN, grade 3/4 infusion reactions, inability to 
reduce corticosteroid dose to ≤10 mg/day within 12 weeks, 
or persistent grade 2/3 AE; withhold for grade 2 pneumon-
itis, grade 2/3 colitis, grade 3/4 endocrinopathies, grade 2 
nephritis, AST/ALT>3-5xULN or bilirubin >1.5-3xULN, or 
grade 3 treatment-related AEs [3]. If toxicity was at-
tributed to one agent, that drug alone could be discontin-
ued [4]. 
Pemetrexed + PC platinum-based chemotherapy + 
matching saline placebo (IV) every 3 weeks for 4 cy-
cles, followed by saline placebo for up to 35 cycles + 
pemetrexed maintenance therapy.  If progression 
occurs, participants may receive pembrolizumab 
every 3 weeks for the remainder of the study or un-
til DP [4]. If toxicity was attributed to one agent, 
that drug alone could be discontinued [4]. 
 
 
 
 
 
Median 
treatment 
duration 
Until DP, unacceptable toxicity, investigator decision, pa-
tient withdrawal or up to 24 months in patients without 
DP; mean DOT was 7.4±4.7 months [4].  
Until DP, unacceptable toxicity, investigator deci-
sion, patient withdrawal, or up to 24 months with-
out DP. Participants with progression may receive 
pembrolizumab every 3 weeks for the remainder of 
the study or until DP; mean DOT was 5.4±4.3 
months [4]. 
Contrain-
dications 
None [3] None 
Drug in-
teractions 
Avoid systemic corticosteroids or immunosuppressants 
prior to starting pembrolizumab [6] Matching saline placebo [4] 
Abbreviations: AE = adverse event; ALT = alanine aminotransferase; AST = aspartate aminotransferase; DOT = duration of treatment; DP = 
disease progression; IV = intravenous; PC = physicians’ choice; ULN = upper limit of normal; USP = United States Pharmacopeia 
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Table 5: Characteristics of the KEYNOTE-189 trial [35] 
Title: Pembrolizumab plus chemotherapy in metastatic NSCLC (KEYNOTE-189) [4, 31] 
Study identifier NCT02578680, EUDRACT2015-003694-15, 3475-189, JAPIC-CTI 163421, MK-3475-189, KEYNOTE-189 
Design International (16 countries), multicentre (126 sites), randomised, double-blind, interventional, phase 
III 
Duration of main phase: February 2016 – March 2017, 965 patients were screened; 
616 patients randomized 2:1 to receive SoC chemotherapy 
plus pembrolizumab (n = 405, pembrolizumab combina-
tion) or saline placebo (n = 202, placebo combination) 
Data cut-off: November 8, 2017; 410 events of progression 
or death and 235 deaths; results reviewed by external mon-
itoring committee January 10, 2018 
Median duration of follow-up: 10 months (range 0.2-20.4) 
Mean duration of treatment: 7.4±4.7 months for pembroli-
zumab combination, 5.4±4.3 months for placebo combina-
tion 
Duration of run-in phase: Not applicable 
Duration of extension phase: At data cut-off, as-treated population, 137 (34%) of pem-
brolizumab combination and 36 (18%) of placebo combina-
tion patients were still receiving assigned treatment. In the 
ITT population, 125 (31%) of pembrolizumab combination 
and 96 (47%) of placebo combination patients received ≥ 1 
subsequent therapy during or outside of the trial. In the pla-
cebo combination group, 67 (33%) had crossed over during 
the trial to receive pembrolizumab monotherapy after pro-
gression; an additional 18 (9%) had received immunother-
apy outside the trial resulting in a 41% cross-over rate in 
the ITT population and 50% in the 170 patients who discon-
tinued all trial drugs.  
Hypothesis 
Superiority 
The primary hypothesis is that pembrolizumab in combination with pemetrexed/platinum chemo-
therapy prolongs PFS and OS compared to pemetrexed/platinum chemotherapy alone.   
Funding Merck, Eli Lilly 
Treatments groups 
 
Pembrolizumab combination 
(n= 405 efficacy; n=405 safety; 
n=137 ongoing at data cut-off; n=82 
treatment post-discontinuation of 
pembrolizumab) 
Pembrolizumab (200 mg IV) + pemetrexed (500 mg/m2 IV 
+ folic acid (300-1000 µg), vitamin B12 (1000 µg) + PC cis-
platin (75 mg/m2 IV) or carboplatin (AUC 5 IV) on day 1 
every 3 weeks for 4 cycles, followed by pembrolizumab 
(200 mg IV) + pemetrexed (500 mg/m2 IV) every 3 weeks 
until progression 
Placebo combination 
(n= 202 efficacy; n=202 safety; 
n=36 ongoing at data cut-off; n=67 
crossed over to pembrolizumab mon-
otherapy post progression) 
Saline placebo (IV) + pemetrexed (500 mg/m2 IV + folic 
acid (300-1000 µg), vitamin B12 (1000 µg) + PC cisplatin 
(75 mg/m2 IV) or carboplatin (AUC 5 IV) on day 1 every 3 
weeks for 4 cycles, followed by saline placebo (IV) + 
pemetrexed (500 mg/m2 IV) every 3 weeks until progres-
sion. If progression occurs, participants may receive pem-
brolizumab every 3 weeks until progression or the remain-
der of the study. 
Notes 
Treatment continued until radiographic progression, unac-
ceptable toxicity, investigator’s decision or patient with-
drawal. If toxicity was clearly attributed to one agent, that 
drug alone could be discontinued.  
Placebo + chemotherapy patients were permitted to cross-
over to pembrolizumab monotherapy after BICR-assessed 
progression.  
Endpoints and definitions 
 
Progression-free survival 
Primary endpoint 
PFS Time from randomization until progression (RECIST v1.1) 
or all-cause death as assessed by BICR (up to 24 months) 
Overall survival  
Primary endpoint OS 
Time from randomization until all-cause death (up to 24 
months) 
Overall response rate 
Secondary endpoint ORR 
The number (%) of patients with confirmed CR or PR (RE-
CIST v1.1) as assessed by BICR (up to 24 months) 
Duration of response 
Secondary endpoint DOR 
Time from first response until progression or death (RE-
CIST v1.1) as assessed by BICR (up to 24 months) 
Adverse events 
Secondary endpoint AEs AEs graded by CTCAE version 4.0 (up to 27 months) 
Discontinued due to ad-
verse events  
Secondary endpoint 
— The number of patients who discontinue study treatment 
due to an AE (up to 24 months) 
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Title: Pembrolizumab plus chemotherapy in metastatic NSCLC (KEYNOTE-189) [4, 31] 
Study identifier NCT02578680, EUDRACT2015-003694-15, 3475-189, JAPIC-CTI 163421, MK-3475-189, KEYNOTE-189 
Database lock Last update posted May 22, 2018 
Results and Analysis  
Analysis description Primary Analysis 
ITT: efficacy analyses included all patients randomized. Safety analysis included all patients who re-
ceived at least one dose of study drug.  
OS and PFS were estimated using Kaplan-Meier method. Data OS data were censored at the time, 
except patients who crossed over. Between-group differences were assessed by stratified log-rank 
test. HRs and 95% CIs were calculated using a stratified Cox proportional-hazards model and 
Efron’s method for handling tied events to assess the magnitude of the treatment difference. Dif-
ferences in RR were assessed with the stratified method of Miettinen and Nurminen. Randomiza-
tion stratification factors were applied to all stratified efficacy analyses.  
Two interim analyses and a final analysis were planned. Family-wise type I error rate was controlled 
at a one-sided alpha of 0.025 using Maurer and Bretz. If a significant benefit in primary endpoints 
was found in the pembrolizumab-combination group, corresponding alpha level was rolled over for 
testing of other primary endpoints. Lan-DeMets O’Brien-Fleming spending function was used to 
control type I error in interim and final analyses.  
A power of 90% was needed to show a HR for progression or death of 0.70 at a one-sided alpha of 
0.0095 (based on 468 events) and a HR of 0.70 for death at a one-sided alpha of 0.0155 (based on 
416 deaths) for comparison between pembrolizumab-combination versus placebo-combination; 
planned enrolment of n = 570. First interim analysis was performed at complete enrolment when 
370 events of progression or death had occurred; approximately 242 deaths would have occurred. 
As of November 8, 2017, there were 410 events of progression or death and 235 deaths. Multiplicity-
adjusted, one-sided alphas at first interim analysis were 0.00559 for PFS and 0.00128 for OS.  
Analysis population   
Inclusion 
 Adults (aged ≥18 years) with pathologically confirmed meta-
static non-squamous NSCLC without sensitizing EGFR or ALK 
mutations without previous systemic therapy 
 Provide tumour sample to determine PD-L1 status 
 Life expectancy ≥ 3 months, adequate organ function with 
ECOG performance-status 0–1 and ≥ 1 measurable lesion ac-
cording to RECIST v1.1 
 Males with female partners, and females of childbearing po-
tential willing to use adequate contraception up to 180 days 
post chemotherapy 
 
Exclusion 
 Received study drug investigational agent, device, antineo-
plastic biological therapy, or had major surgery <3 weeks prior 
to first pembrolizumab dose 
 Received a live-virus vaccination within 30 days of starting 
study 
 Is expected to require antineoplastic therapy during the study 
 History of HIV, hepatitis B or C, psychiatric or substance abuse 
disorder, non-infectious pneumonitis requiring glucocorticoids, 
clinically active diverticulitis, intra-abdominal abscess, sympto-
matic CNS metastases, gastrointestinal obstruction or perito-
neal carcinomatosis 
 Active autoimmune disease, receiving systemic immunosup-
pressive treatment or having received ≥ 30 Gy of radiotherapy 
to the lung within previous 6 months 
 Known hypersensitivity to monoclonal antibody, cisplatin, car-
boplatin or pemetrexed 
 Pregnant, breastfeeding, or expecting to conceive or father 
children prior to 120 days after last dose of study medication 
through 180 days after last dose of chemotherapy 
Characteristics 
Pembrolizumab 
combination 
(n = 410) 
Placebo combination 
(n = 206) 
Total 
(n = 616) 
Age 
  Median age (range), years 
  <65 years, n (%) 
 
65.0 (34.0-84.0) 
197 (48.0) 
 
63.5 (34.0-84.0) 
115 (55.8) 
 
64.3 (34.0-84.0) 
312 (50.6) 
Male, n (%) 254 (62.0) 109 (52.9) 363 (58.9) 
Region of enrolment, n (%) 
  Europe 
  North America 
  East Asia 
  Other region 
 
243 (59.3) 
111 (27.1) 
4 (1.0) 
52 (12.7) 
 
131 (63.6) 
46 (22.3) 
6 (2.9) 
23 (11.2) 
 
374 (60.7) 
157 (25.5) 
10 (1.6) 
75 (12.2) 
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Title: Pembrolizumab plus chemotherapy in metastatic NSCLC (KEYNOTE-189) [4, 31] 
Study identifier NCT02578680, EUDRACT2015-003694-15, 3475-189, JAPIC-CTI 163421, MK-3475-189, KEYNOTE-189 
ECOG performance-status, n 
(%) 
  0 
  1 
  2 
 
 
186 (45.4) 
221 (53.9) 
1 (0.2) 
 
 
80 (38.8) 
125 (60.7) 
0 (0.0) 
 
 
266 (43.2) 
346 (56.2) 
1 (0.2) 
Smoking status, n (%) 
  Current or former 
  Never 
 
362 (88.3) 
48 (11.7) 
 
181 (87.9) 
25 (12.1) 
 
543 (88.1) 
73 (11.9) 
Histological features, n (%) 
  Adenocarcinoma 
  Unspecified NSCLC 
  Other 
 
394 (96.1) 
10 (2.4) 
6 (1.5) 
 
198 (96.1) 
4 (1.9) 
4 (1.9) 
 
592 (96.1) 
14 (2.3) 
10 (1.6) 
Brain metastases, n (%) 73 (17.8) 35 (17.0) 108 (17.5) 
PD-L1 tumour score, n (%) 
  <1% 
  ≥1% 
  1–49% 
  ≥50% 
  Not evaluable 
 
127 (31.0) 
260 (63.4) 
128 (31.2) 
132 (32.2) 
23 (5.6) 
 
63 (30.6) 
128 (62.1) 
58 (28.2) 
70 (34.0) 
15 (7.3) 
 
190 (30.8) 
388 (63.0) 
186 (30.2) 
202 (32.8) 
38 (6.2) 
Previous therapy for non-
metastatic disease 
  Thoracic radiotherapy 
  Neoadjuvant therapy 
  Adjuvant therapy 
 
 
28 (6.8) 
5 (1.2) 
25 (6.1) 
 
 
20 (9.7) 
6 (2.9) 
14 (6.8) 
 
 
48 (7.8) 
11 (1.8) 
39 (6.3) 
Applicability of evidence 
Population 
KEYNOTE-189 was conducted in patients with PD-L1-positive metastatic non-squamous NSCLC 
without EGFR or ALK mutations. Generalizability of the results may be limited in that while study 
participants were a median age of 64 years with good performance status, the average age at diag-
nosis is 70 years. The clinical specificity in elderly patients with comorbidities, reduced functional 
reserve, and immunosenescence may affect the efficacy and or toxicity of pembrolizumab.  
Intervention 
The dosage and administration of pembrolizumab used in KEYNOTE-189 is consistent with that rec-
ommended for the treatment of NSCLC [3]. Dose reductions or interruptions were allowed and one 
agent alone could be discontinued if it caused toxicity. Cross-over to pembrolizumab monotherapy 
was permitted for placebo combination patients with verified disease progressions.  
Comparators 
Based on results of the KEYNOTE-024 study pembrolizumab became a first-line monotherapy option 
for patients with metastatic NSCLC whose tumours express high levels of PD-L1. Without direct 
comparison trials, physicians and patients may need to discuss whether adding pembrolizumab to 
pemetrexed and platinum-based therapy would provide greater individualised efficacy than pem-
brolizumab monotherapy. 
Outcomes 
No evidence was reported regarding the effect of pembrolizumab on generic or disease-specific QoL 
of CNS activity. QoL measures are needed to ensure patients achieve a clinically relevant benefit 
over time despite favourable tolerability, especially as other immunotherapies are not considered 
for comparison. NSCLC patients frequently present with brain metastases; there is concern regarding 
the ability of pembrolizumab to penetrate the blood brain barrier. 
Setting KEYNOTE-189 was a multination, multicentre study where approximately 61% of patients were Eu-
ropean, 26% were North American, 2% were East Asian, and 12% were from other regions.  
Abbreviations: ALK = anaplastic lymphoma kinase; AUC = area under the curve; BICR = blinded independent central review; CI = confidence 
interval; CNS = central nervous system; ECOG = Eastern Cooperative Oncology Group; EGFR = Epidermal Growth Factor Receptor; Gy = 
gray; HIV = Human Immunodeficiency Virus; HR = hazard ratio; IV = intravenous; ITT = intention-to-treat; NSCLC = non-small cell lung 
cancer; ORR = overall response rate; OS = overall survival; PC = physician’s choice; PD-L1 = programmed death ligand 1; PFS = progression-
free survival; RECIST = Response Evaluation Criteria in Solid Tumours; RR = response rate; SoC = standard of care 
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Table 6: Risk of bias assessment on study level is based on EUnetHTA [32, 34] 
Criteria for judging risk of bias  Risk of bias 
Adequate generation of randomisation sequence: randomised 2:1 to pembrolizumab combina-
tion or placebo combination using the IVRS/IWRS system. Randomization was stratified ac-
cording to PD-L1 expression (TPS, ≥1% versus <1%), choice of platinum-based drug (cisplatin 
versus carboplatin), and smoking history (never versus former or current).  
yes 
Adequate allocation concealment: Study site’s unblinded pharmacist obtained each subject’s 
study identification number and study drug assignment from the IVRS/IWRS and prepared 
ready-to use blinded pembrolizumab/saline solutions for infusion.  
yes 
Blinding: 
Patient: Study identification numbers and drug assignments were obtained 
from the IVRS/IWRS by an unblinded pharmacist who prepared blinded so-
lutions packaged identically to maintain blinding. 
yes 
Treating physician: The unblinded pharmacist provided investigative staff 
with ready-to-use blinded pembrolizumab/saline infusion solutions pack-
aged identically to maintain blinding. 
yes 
Outcome assessor: centralised randomisation and allocation; central imag-
ing vendor blinded to treatment assignment to minimize bias in response 
assessments; BICR assessed efficacy and safety at pre-specified interim 
analyses; sensitivity analysis was planned to assess OS, PFS and ORR by pre-
defined subgroups. AEs and safety data were investigator-assessed and im-
mune-mediated AEs were defined on the basis of a list of terms specified by 
the sponsor.  
yes 
Selective outcome reporting unlikely: primary endpoints include BICR-assessed PFS, OS, ORR, 
DOR, investigator-assessed PFS and safety. Other endpoints that are not included in this anal-
ysis are PROs, biomarker research and pharmacokinetics, as per protocol.  
yes 
No other aspects which increase the risk of bias: industry funded the study, assisted with study 
design, data collection, analysis, interpretation, manuscript preparation and review. Placebo 
combination patients (n = 67) crossed over to pembrolizumab monotherapy post progression. 
no 
Risk of bias – study level low-risk 
Abbreviations: BICR = blinded independent central review; DOR = duration of response; IVRS/IWRS = interactive web response system; 
interactive web response system; OS = overall survival; ORR = overall response rate; PD-L1 = programmed death ligand 1; PFS = progres-
sion-free survival; PROs = patient reported outcomes; TPS = tumour proportion score 
